Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug—naive patients with type 2 diabetes: A randomized, double-blind, placebo-controlled, parallel-group study
References (30)
- et al.
Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: A multinational, randomized, open-label, two-period, crossover noninferiority trial
Clin Ther
(2007) Glycemic management of type 2 diabetes: An emerging strategy with oral agents, insulins, and combinations
Endocrinol Metab Clin North Am
(2005)- et al.
A randomized, open-label, crossover study examining the effect of injection site on bioavailability of exenatide (synthetic exendin-4)
Clin Ther
(2005) - et al.
A rapid method for the determination of glycosylated hemoglobins using high pressure liquid chromatography
Metabolism
(1978) New technologies and therapies in the management of diabetes
Am J Manag Care
(2007)- et al.
Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes
Diabetes Care
(2004) - et al.
Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes
Diabetes Care
(2005) - et al.
Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea
Diabetes Care
(2005) - et al.
The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: A randomized trial [published correction appears in Ann Intern Med 2007;146:896]
Ann Intern Med
(2007)
Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: A randomized trial
Ann Intern Med
(2005)
A comparison of twice- daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: A non-inferiority study
Diabetologia
(2007)
Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years
Curr Med Res Opin
(2008)
Exenatide improves glycemic control and reduces body weight in subjects with type 2 diabetes: A dose-ranging study
Diabetes Technol Ther
(2005)
The incretin mimetic exenatide as a monotherapy in patients with type 2 diabetes
Diabetes Technol Ther
(2007)
Cited by (314)
The effect of subcutaneous Lixisenatide on weight loss in patients with type 2 Diabetes Mellitus: Systematic review and Meta-Analysis of randomized controlled trials
2024, Diabetes Research and Clinical PracticeComparative effects of glucagon-like peptide-1 receptors agonists, 4-dipeptidyl peptidase inhibitors, and metformin on metabolic syndrome
2023, Biomedicine and PharmacotherapyCardiovascular outcomes trials with incretin-based medications: a critical review of data available on GLP-1 receptor agonists and DPP-4 inhibitors
2020, Metabolism: Clinical and Experimental
These data were presented in part at the 68th Scientific Sessions of the American Diabetes Association, June 6–10, 2008, San Francisco, Calif.
Copyright © 2008 Published by Elsevier Inc.